MLYS - Conference and earnings call announcements

RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS),  a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami on June 8-10, 2026. Goldman Sachs 47th Annual Global Healthcare ConferenceDate:Tuesday, June 9, 2026Time:2:40pm ETFormat:Fireside ChatWebcast Link      A live webcast of this fireside chat can also be accessed on the "News & Events" page

RADNOR, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Jefferies 2026 Global Healthcare Conference being held in New York on June 2-4, 2026. Jefferies Global Healthcare ConferenceDate:Wednesday, June 3, 2026Time:7:35am EDTFormatCorporate PresentationWebcast Link A live webcast of this presentation can also be accessed on the "News & Events" page in the Investor Relati

RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced that management will be participating in the Bank of America Securities 2026 Health Care Conference being held in Las Vegas on May 11-14, 2026. Bank of America Securities Health Care ConferenceDate:Tuesday, May 12, 2026Time:9:20am PTFormat:Fireside ChatWebcast Link    A live webcast of this fireside chat can also be accessed on the "News & Events" page in the Inve

RADNOR, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that members of senior management will be participating in fireside chats at three upcoming investor conferences. Guggenheim Healthcare Innovation ConferenceDate:Tuesday, November 11, 2025Time:9:30am ETFormat:Fireside ChatWebcast Link   Stifel Healthcare ConferenceDate:Thursday, November 13, 2025Time:2:00pm ETFormat:Fireside ChatWebcast Link 

RADNOR, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Bank of America Securities 2025 Health Care Conference being held in Las Vegas on May 12-15, 2025. Bank of America Securities Health Care ConferenceDate: Wednesday, May 14, 2025Time: 4:35pm PDTFormat: PresentationWebcast Link    A live webcast of the presentation can be accessed under "News and Events" on the Investor Relations s

RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in fireside chats at three upcoming investor conferences. Guggenheim Healthcare Innovation Conference:Date:Tuesday, November 12, 2024Time:4:00pm ESTFormat:Fireside ChatWebcast Link   Stifel Healthcare Conference:Date:Tuesday, November 19, 2024Time:10:20am ESTFormat:Fireside ChatWebcast Link   Evercore ISI HealthCONx ConferenceDate:Wednesday, December 4, 2024Time:4:15

RADNOR, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Wells Fargo Healthcare Conference, being held in Boston, MA on September 4-6, 2024.  Wells Fargo Healthcare ConferenceDate:Time:Format:Webcast LinkThursday, September 5, 20241:30pm EDTFireside Chat   A live webcast of the fireside chat can be accessed under "News and Events" on the Investor Relations section of the Mineralys websi

RADNOR, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference, being held in Miami, FL on June 10-13, 2024. Goldman Sachs 45th Annual Global Healthcare Conference:Date:Tuesday, June 11, 2024Time:4:00pm EDTFormat:Fireside ChatWebcast Link   A live webcast of the fireside chat can be accessed under "News and Events" on the Investor Relations section o

RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference, being held in Las Vegas on May 14-16, 2024. Bank of America Securities Health Care Conference:Date:Wednesday, May 15, 2024Time:5:00pm PDTFormat:Fireside Chat   A live webcast of the fireside chat can be accessed by clicking here or under "News and Events" on the Investor Relations section of t

RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that Chief Executive Officer Jon Congleton will be participating in a fireside chat at the Guggenheim Securities 6th Annual Biotechnology Conference, being held in New York City on February 7-8, 2024. Guggenheim Securities 6th Annual Biotechnology Conference:Date: Thursday, February 8, 2024Time: 9:00am ESTFormat:Fireside Chat A live webcast of the fireside chat can be accessed under "News and Event

– Topline data from confirmatory Launch-HTN trial expected in 2H 2025 – – Topline data from ongoing Advance-HTN pivotal trial expected in 2H 2024 – RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that the first subject has been dosed in the Launch-HTN (NCT06153693) pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on ther

RADNOR, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that members of the senior management will be participating in the Stifel Healthcare Conference being held in New York on November 14-15, the Jefferies London Healthcare Conference being held in London on November 14-16, and the Evercore ISI 6th Annual HealthCONx Conference being held in Miami on November 28-30. Stifel Healthcare Conference:Date: Wednesday, November 15, 2023Time: 12:40pm ESTFormat:

RADNOR, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference in New York on Thursday, September 28, 2023 at 9:10 a.m. ET. Cantor Fitzgerald Global Healthcare Conference: Date: Thursday, September 28, 2023  Time:9:10 a.m. ET  Webcast: A live webcast of the fi

RADNOR, Pa., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will participate in a fireside chat at the Wells Fargo Securities Healthcare Conference in Boston, Massachusetts on Thursday, September 7, 2023 at 8:45 a.m. ET. The live webcast of the fireside chat can be accessed under "News and Events" on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay

RADNOR, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will be giving a presentation at the Jefferies Healthcare Conference in New York at 9:30 a.m. ET on Friday, June 9, 2023. The live webcast of the presentation can be accessed under "News and Events" on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the webcast will be available on the Company'

– Topline data from the trial are expected in the first half of 2024 – – A second, pivotal trial of lorundrostat in uncontrolled and resistant hypertension expected to commence enrollment in the second half of 2023 – RADNOR, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced the first patient dosed in the ADVANCE-HTN pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN) when used as an add-on therapy to s

RADNOR, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton and Chief Financial Officer and Chief Business Officer Adam Levy will participate in a fireside chat at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 10, 2023 at 5 p.m. PT The live webcast of the fireside chat can be accessed under "News and Events" on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the webcast w